Long-term evolution of anti-INFbeta antibodies in IFNbeta-treated MS patients: the London, Canada, MS Clinic experience.
Kremenchutzky
Marcelo
M
Department of Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, Canada. Marcelo.Kremenchutzky@lhsc.on.ca
D000046:Academic Medical Centers / Q000706:statistics & numerical data; D000906:Antibodies / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D019204:GTP-Binding Proteins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000276:immunology* / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D064547:Myxovirus Resistance Proteins; D009864:Ontario; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D013995:Time
D000906:Antibodies; D064547:Myxovirus Resistance Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D019204:GTP-Binding Proteins